Acta Med. 2021, 64: 64-69

https://doi.org/10.14712/18059694.2021.12

Α Case of Severe Thyroid Eye Disease Treated with Tocilizumab

Aysel Mehmeta, Eirini Kanella Panagiotopouloua, Aristeidis Konstantinidisa, Charalampos Papagorasb, Panagiotis Skendrosb, Doukas Dardabounisa, Athanasia Maria Mikropouloua, Georgios Labirisa

aUniversity Eye Clinic, University Hospital of Alexandroupolis, Greece
bUniversity Department of Internal Medicine, University Hospital of Alexandroupolis, Greece

Received November 10, 2020
Accepted January 18, 2021

References

1. Barrio-Barrio J, Sabater LA, Bonet-Farriol E, Velázquez-Villoria A, Galofré JC. Graves’ Ophthalmopathy: VISA versus EUGOGO Classification, Assessment, and Management. J Ophthalmol 2015; 2015: 249125. <https://doi.org/10.1155/2015/249125> <PubMed>
2. Bartalena L. What to do for moderate-to-severe and active Graves’ orbitopathy if glucocorticoids fail? Clin Endocrinol (Oxf) 2010; 73(2): 149–52.
3. Hamed Azzam S, Kang S, Salvi M, Ezra DG. Tocilizumab for thyroid eye disease. Cochrane Database Syst Rev 2018; 11: CD012984.
4. Bartalena L, Baldeschi L, Boboridis K, et al. The 2016 European Thyroid Association/European Group on Graves’ Orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 2016; 5(1): 9–26. <https://doi.org/10.1159/000443828> <PubMed>
5. Strianese D, Rossi F. Interruption of autoimmunity for thyroid eye disease: B-cell and T-cell strategy. Eye (Lond) 2019; 33(2): 191–9. <https://doi.org/10.1038/s41433-018-0315-9> <PubMed>
6. Shams PN, Ma R, Pickles T, Rootman J, Dolman PJ. Reduced risk of compressive optic neuropathy using orbital radiotherapy in patients with active thyroid eye disease. Am J Ophthalmol 2014; 157(6): 1299–305. <https://doi.org/10.1016/j.ajo.2014.02.044>
7. Marcocci C, Bartalena L, Bogazzi F, Bruno-Bossio G, Lepri A, Pinchera A. Orbital radiotheraphy combined with high-dose systemic glucocorticoids for Graves’ ophthalmopathy is more effective than orbital radiotherapy alone: results of a prospective study. J Endocrinol Invest 1991; 14: 853–60. <https://doi.org/10.1007/BF03347943>
8. Perez-Moreiras JV, Gomez-Reino JJ, Maneiro JR, et al. Tocilizumab in Graves Orbitopathy Study Group. Efficacy of Tocilizumab in Patients With Moderate-to-Severe Corticosteroid-Resistant Graves Orbitopathy: A Randomized Clinical Trial. Am J Ophthalmol 2018; 195: 181–90. <https://doi.org/10.1016/j.ajo.2018.07.038>
9. Maldiney T, Deschasse C, Bielefeld P. Tocilizumab for the Management of Corticosteroid-Resistant Mild to Severe Graves’ Ophthalmopathy, a Report of Three Cases. Ocul Immunol Inflamm 2020; 28(2): 281–4. <https://doi.org/10.1080/09273948.2018.1545914>
10. Erdoğan MF, Demir O, Ersoy RU, et al. Comparison of Early Total Thyroidectomy with Antithyroid Treatment in Patients with Moderate- Severe Graves’ Orbitopathy: A Randomized Prospective Trial. Eur Thyroid J 2016; 5(2): 106–11. <https://doi.org/10.1159/000444796> <PubMed>
11. Sy A, Eliasieh K, Silkiss RZ. Clinical Response to Tocilizumab in Severe Thyroid Eye Disease. Ophthalmic Plast Reconstr Surg 2017; 33(3): e55–e57. <https://doi.org/10.1097/IOP.0000000000000730>
12. Weber KJ, Solorzano CC, Lee JK, Gaffud MJ, Prinz RA. Thyroidectomy remains an effective treatment option for Graves’ disease. Am J Surg 2006; 191: 400–5. <https://doi.org/10.1016/j.amjsurg.2005.10.043>
front cover

ISSN 1211-4286 (Print) ISSN 1805-9694 (Online)

Open access journal

Archive